Biological Activity of Organo Silicon Compounds -Study on Cancer Chemotherapeutic Activity-

Abstract

Fifty organo silicon compounds were screened as to their antitumor effect by using several animal transplantable tumors such as Ehrlich carcinoma (EHC), Sarcoma-180 (S-180), Lewis lung carcinoma (LLC), B-16 melanoma (B-16 M), L-1210 and P-388 leukemia. Among these compounds, 2-(2-trimethylsilylethyl)thioethylamine (SDK-12 A) was found to be effective by oral administration on solid tumors of EHC, S-180, LLC and B-16 M, but SDK-12 A was found to be ineffective on L-1210 and P-388 leukemia.
The effect on EHC, S-180 and B-16 M was superior to that of 5-FU administered intraperitoneally and the effect on LLC was equivalent to that of 5-FU. SDK-12 A was found to be low toxic and after the oral administration of 1/5 LD50/day to mice for 10 days, any toxic symptoms were not observed.
This compound showed an inhibitory effect on the metastasis of both of B-16 M and LLC. Furthermore, SDK-12 A showed activation of the delayed type hypersensitivity response of mice bearing B-16 M. From these findings, it may be suggested that SDK-12 A is a unique drug possessing a dual effect for inhibition of the tumor growth and activation of the delayed type cellular immunity.